Chlamydia Infection Diagnostics Market: as FDA clearances extend molecular testing from the clinic into the home, chlamydia diagnosis shifts from a multi-day laboratory referral into a same-visit or self-administered result, so single-visit treatment becomes achievable for the first time at population scale, and platform vendors that combine CLIA-waived point-of-care speed with at-home accessibility are capturing volume from centralized reference laboratories.

The global chlamydia infection diagnostics market size was USD 1.42 Billion in 2025 and is expected to register a revenue CAGR of 7.8% during the forecast period. Market revenue growth is driven by factors such as FDA clearances for CLIA-waived point-of-care molecular testing platforms, the expansion of at-home self-collection and self-testing options, and rising public health screening initiatives targeting asymptomatic chlamydia infection. The first driving factor is the shift from centralized laboratory testing to point-of-care molecular diagnosis that enables same-visit treatment. Roche received FDA 510(k) clearance and a CLIA waiver in January 2025 for its cobas liat sexually transmitted infection multiplex assay panels, enabling clinicians to diagnose chlamydia and gonorrhea from a single sample with results in approximately 20 minutes rather than the multi-day turnaround of centralized laboratory testing. The second driving factor is the FDA’s extension of molecular STI testing into fully at-home, prescription-free formats. The FDA granted marketing authorization in March 2025 to the Visby Medical Women’s Sexual Health Test, the first over-the-counter diagnostic test for chlamydia, gonorrhea, and trichomoniasis that can be purchased without a prescription and used entirely at home. The third driving factor is sustained public health screening investment targeting the estimated 2.2 million annual chlamydia and gonorrhea diagnoses reported in the United States. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single FDA-cleared multiplex molecular panel widens its own revenue base as additional pathogen targets are added to the same cartridge or platform, letting one cleared instrument capture incremental laboratory and point-of-care revenue without a new hardware placement for each new test. Once a molecular diagnostics platform is placed in a clinic or laboratory, each additional FDA-cleared assay added to its menu, such as a combined chlamydia, gonorrhea, and Mycoplasma genitalium panel, adds new billable test volume without requiring a new instrument purchase, so the value of an already-placed platform compounds as its assay menu grows around it. As a result, demand and revenue share are concentrating around platforms with the broadest FDA-cleared multiplex STI panel menus, and the forecast tilts toward combined multi-pathogen panels rather than single-target chlamydia-only tests. For instance, in January 2025, Roche, Switzerland, received FDA clearance for cobas liat panels combining chlamydia and gonorrhea testing with an additional Mycoplasma genitalium target on the same already-placed point-of-care instrument, one of a growing number of pathogen combinations the cobas liat platform now supports without a new hardware placement. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the FDA’s extension of CLIA-waived status to molecular STI testing platforms capable of delivering results within a single clinical visit. Same-visit diagnosis works only if a test is both fast enough to complete during a routine appointment and simple enough to run without a certified laboratory technician, and CLIA waiver status certifies exactly that combination, so FDA clearance and CLIA waiver approval have become the gating event for point-of-care STI platform commercial launch. Roche received FDA 510(k) clearance and a CLIA waiver in January 2025 for its cobas liat sexually transmitted infection multiplex assay panels, delivering chlamydia and gonorrhea results in approximately 20 minutes at the point of care rather than the multi-day turnaround typical of centralized laboratory testing. The recent record shows the pace. In March 2025, the FDA granted marketing authorization to the Visby Medical Women’s Sexual Health Test as the first over-the-counter, prescription-free, fully at-home molecular test for chlamydia, gonorrhea, and trichomoniasis. The effect on the market is that same-visit and same-day treatment is becoming achievable at a population scale that centralized laboratory testing structurally could not support. These are some of the key factors driving revenue growth of the market.

The second driver is the FDA’s willingness to authorize fully at-home molecular STI testing without requiring a clinical visit at any stage. At-home testing works only if analytical performance in an at-home setting matches clinic-administered testing, and demonstrating that equivalence through FDA review has been the key regulatory hurdle, so at-home authorization and platform miniaturisation have advanced together. The Visby Medical Women’s Sexual Health Test, authorized in March 2025, delivers results in approximately 30 minutes from a self-collected vaginal swab using a single-use, handheld PCR device requiring no external instrumentation or cold-chain logistics. The test addresses fear and anxiety-related delayed diagnosis documented among patients reluctant to seek in-person sexual health testing, extending reach into populations that centralized or even point-of-care clinical testing does not capture. The effect on the market is that at-home testing volume is emerging as a distinct revenue channel alongside, rather than purely substituting for, clinical point-of-care testing. These are some of the key factors driving revenue growth of the market.

“The Visby Medical Women’s Sexual Health Test, authorized by the FDA in March 2025, is the first over-the-counter molecular diagnostic for chlamydia, gonorrhea, and trichomoniasis that a patient can purchase and use entirely without a prescription or clinic visit.”

The third driver is the expansion of FDA-cleared multiplex STI panels that test for multiple pathogens from a single sample on an already-placed instrument. Multiplex testing works only if a laboratory or point-of-care site has already invested in the underlying instrument platform, and each additional cleared pathogen target then adds test volume without additional capital cost, so instrument placement and menu expansion reinforce each other over time. Roche’s cobas liat platform, cleared in January 2025, offers panels combining chlamydia and gonorrhea testing with an additional Mycoplasma genitalium target, while Hologic’s Panther system supports an expanding menu of Aptima-branded STI assays on the same installed instrument base. The effect on the market is that instrument placement economics increasingly favour vendors with the broadest cleared multiplex menu over vendors offering only a standalone chlamydia test. These are some of the key factors driving revenue growth of the market.

However, the chlamydia infection diagnostics market faces severe adoption constraints from reimbursement gaps for asymptomatic screening, the cost of point-of-care molecular platforms relative to send-out testing, and unresolved care-linkage questions for self-administered results. Because asymptomatic chlamydia and gonorrhea screening in average-risk populations is not reimbursable through the Centers for Medicare and Medicaid Services even where the United States Preventive Services Task Force recommends screening for sexually active women 24 years and younger and older women at increased risk, public health clinics and primary care providers face a structural funding gap that caps screening volume growth regardless of test availability or accuracy. Point-of-care platform economics are a second constraint, because CLIA-waived molecular instruments carry per-cartridge costs and ongoing service contract fees that are meaningfully more expensive than batched send-out laboratory testing, and some platforms carry costly service contracts with volume-based pricing implications that strain smaller, budget-constrained clinic operating models. Result reporting and care linkage fragmentation is the third constraint, since at-home and self-administered tests raise open questions about how a positive result connects a patient to treatment, partner notification, and public health case reporting, so public health authorities remain cautious about treating at-home results as equivalent to laboratory-based, surveillance-linked testing for CDC case count purposes. These factors substantially limit chlamydia infection diagnostics market growth over the forecast period.

Based on test type, the global chlamydia infection diagnostics market is segmented into nucleic acid amplification tests, rapid antigen tests, and culture and direct fluorescent antibody tests. NAAT holds the largest revenue share, because it remains the CDC-recommended gold standard for chlamydia detection given its superior sensitivity relative to antigen-based methods, which suits both centralized laboratory and point-of-care molecular platform revenue models. Rapid antigen tests remain established in lower-resource and field-testing settings, and they are cheaper per test with no instrument requirement, but they cannot match NAAT sensitivity, particularly for asymptomatic or low-bacterial-load infections. Culture and direct fluorescent antibody testing is expected to register the slowest revenue trajectory in the global chlamydia infection diagnostics market over the forecast period, continuing a long-run decline as NAAT-based point-of-care and at-home platforms from Roche and Visby Medical capture volume once served by traditional laboratory culture.

PCR-based molecular platforms are expected to account for a significantly large revenue share in the global chlamydia infection diagnostics market during the forecast period

Based on technology, the global chlamydia infection diagnostics market is segmented into PCR-based molecular platforms, transcription-mediated amplification, and isothermal amplification. PCR-based platforms hold the largest revenue share, because Roche’s cobas liat and Cepheid’s Xpert platforms both use real-time PCR chemistry and dominate the CLIA-waived point-of-care segment, which suits the multiplex panel expansion strategy that vendors are pursuing. Isothermal amplification is expected to register the fastest revenue growth rate in the global chlamydia infection diagnostics market over the forecast period, driven by its compatibility with battery-powered, instrument-free formats, which is why Visby Medical’s at-home test uses isothermal-adjacent single-use PCR technology to eliminate external hardware requirements.

Based on sample type, the global chlamydia infection diagnostics market is segmented into vaginal swab, urine, endocervical/urethral swab, and extragenital swab sample types. Vaginal swab holds the largest revenue share, because both self-collected and clinician-collected vaginal swabs are validated across the leading FDA-cleared platforms, which suits the shift toward self-collection in both point-of-care and at-home settings. Extragenital swab sampling is expected to register rapid revenue growth in the global chlamydia infection diagnostics market over the forecast period, driven by CDC guidance recommending rectal and pharyngeal screening in higher-risk populations, which is why Hologic’s Aptima Combo 2 and Cepheid’s Xpert CT/NG both carry FDA-cleared extragenital claims.

Based on regional analysis, the chlamydia infection diagnostics market in North America accounted for largest revenue share in 2025. The United States leads because it reports the highest absolute chlamydia case volume of any country tracked by the CDC Sexually Transmitted Infections Surveillance Report, and because Roche, Hologic, Cepheid, and Visby Medical, four of the leading global molecular STI diagnostics vendors, concentrate their commercial and regulatory activity in the US FDA clearance pathway. Roche’s January 2025 FDA clearance for cobas liat STI panels and Visby Medical’s March 2025 at-home test authorization both launched first in the United States market. The concentration of FDA clearance activity in the United States also means new point-of-care and at-home molecular STI platforms are typically launched in the United States before other regions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national chlamydia diagnostics markets within Europe. The European Medicines Agency’s CE-IVD marking pathway under the In Vitro Diagnostic Regulation moves more deliberately than the FDA’s single-agency clearance process, and national health system procurement cycles for point-of-care instruments add further lead time. The result is steady rather than rapid growth, shaped more by regulatory and procurement cadence than by underlying clinical demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, India, and Japan represent the three largest national chlamydia diagnostics markets within the region. Rising government investment in sexual health screening infrastructure and expanding private diagnostic laboratory networks in China and India are driving molecular testing adoption from a comparatively low installed base, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national chlamydia diagnostics markets within the region. Public health screening programmes in both countries are expanding NAAT-based testing capacity, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the molecular diagnostic instruments and reagents that Latin American laboratories depend on through 2026, slowing adoption beyond the region’s main urban health systems.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial chlamydia diagnostics markets within the GCC. The UAE is the most established chlamydia diagnostics market on the continent given its concentrated private healthcare infrastructure, while the wider Gulf states and broader African markets are still building molecular STI testing capacity from scratch.